| Bacterial induction of autoantibodies to β2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome M Blank, I Krause, M Fridkin, N Keller, J Kopolovic, I Goldberg, A Tobar, ... The Journal of clinical investigation 109 (6), 797-804, 2002 | 436 | 2002 |
| All-D-magainin: chirality, antimicrobial activity and proteolytic resistance R Bessalle, A Kapitkovsky, A Gorea, I Shalit, M Fridkin FEBS letters 274 (1-2), 151-155, 1990 | 404 | 1990 |
| CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma O Mandelboim, G Berke, M Fridkin, M Feldman, M Eisenstein, ... Nature 369 (6475), 67-71, 1994 | 346 | 1994 |
| Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos P Gressens, JM Hill, I Gozes, M Fridkin, DE Brenneman Nature 362 (6416), 155-158, 1993 | 345 | 1993 |
| Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases H Zheng, LM Weiner, O Bar-Am, S Epsztejn, ZI Cabantchik, ... Bioorganic & medicinal chemistry 13 (3), 773-783, 2005 | 322 | 2005 |
| Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes Y Shechter, I Goldwaser, M Mironchik, M Fridkin, D Gefel Coordination Chemistry Reviews 237 (1-2), 3-11, 2003 | 307 | 2003 |
| Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity … H Zheng, S Gal, LM Weiner, O Bar‐Am, A Warshawsky, M Fridkin, ... Journal of neurochemistry 95 (1), 68-78, 2005 | 251 | 2005 |
| Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine … S Gal, H Zheng, M Fridkin, MBH Youdim Journal of neurochemistry 95 (1), 79-88, 2005 | 234 | 2005 |
| Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides M Blank, Y Shoenfeld, S Cabilly, Y Heldman, M Fridkin, ... Proceedings of the National Academy of Sciences 96 (9), 5164-5168, 1999 | 225 | 1999 |
| Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides O Mandelboim, E Vadai, M Fridkin, A Katz-Hillel, M Feldman, G Berke, ... Nature medicine 1 (11), 1179-1183, 1995 | 215 | 1995 |
| Insulin-like effects of vanadium: basic and clinical implications I Goldwaser, D Gefel, E Gershonov, M Fridkin, Y Shechter Journal of inorganic biochemistry 80 (1-2), 21-25, 2000 | 210 | 2000 |
| Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. P Gressens, S Marret, JM Hill, DE Brenneman, I Gozes, M Fridkin, ... The Journal of clinical investigation 100 (2), 390-397, 1997 | 210 | 1997 |
| Structure− function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria H Tsubery, I Ofek, S Cohen, M Fridkin Journal of medicinal chemistry 43 (16), 3085-3092, 2000 | 206 | 2000 |
| Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor α transcriptional activation by regulating nuclear factor-kB … M Delgado, EJ Munoz-Elias, Y Kan, I Gozes, M Fridkin, DE Brenneman, ... Journal of Biological Chemistry 273 (47), 31427-31436, 1998 | 196 | 1998 |
| A synthesis of cyclic peptides utilizing high molecular weight carriers M Fridkin, A Patchornik, E Katchalski Journal of the American Chemical Society 87 (20), 4646-4648, 1965 | 188 | 1965 |
| Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease D Offen, Y Sherki, E Melamed, M Fridkin, DE Brenneman, I Gozes Brain research 854 (1-2), 257-262, 2000 | 185 | 2000 |
| Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides DE Brenneman, J Hauser, E Neale, S Rubinraut, M Fridkin, A Davidson, ... Journal of Pharmacology and Experimental Therapeutics 285 (2), 619-627, 1998 | 181 | 1998 |
| Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist JR Glowa, LV Panlilio, DE Brenneman, I Gozes, M Fridkin, JM Hill Brain research 570 (1-2), 49-53, 1992 | 177 | 1992 |
| Death-associated protein (DAP) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons D Pelled, T Raveh, C Riebeling, M Fridkin, H Berissi, AH Futerman, ... Journal of Biological Chemistry 277 (3), 1957-1961, 2002 | 176 | 2002 |
| Therapeutic targets and potential of the novel brain‐permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease 1 Y Avramovich‐Tirosh, T Amit, O Bar‐Am, H Zheng, M Fridkin, ... Journal of neurochemistry 100 (2), 490-502, 2007 | 171 | 2007 |
